Theralase Technologies Inc. V.TLT

bladder, brain, lung, esophagus

[floatinketucky]

UHN and UT researchers will specifically focus on developing algorithms focused on optimizing and predicting patient response to PDT when treated for a range of cancers, including: bladder, brain, lung, esophagus, head and neck and female reproductive organs. The safety and efficacy of the PDT will be tested and validated initially in animals and with that knowledge, the optimized procedures will be subsequently transferred into various human clinical studies.
____________________________________________
Additional Theralase cancer research

Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer Toronto, Ontario – September 19, 2017

 

Theralase® Anti-Cancer Vaccine Validated in Colorectal Cancer

November 22, 2017

Theralase® Advances Anti-Cancer Technology in Destruction of Human Lung Cancer Toronto, Ontario – March 5, 2018

 

Theralase® Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer

Toronto, Ontario – March 27, 2018

[floatinketucky]

Theralase® Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System Theralase® Affiliated Researchers Present New Data that Demonstrates the Application of Theralase’s Lead Photo Dynamic Compound, TLD-1433, in the Destruction of Gastrointestinal Dysplasia and Esophageal Cancer. Theralase® Anti-Cancer Technology Shows

[Gooseybear]

Old article. Any new outcomes?

[floatinketucky]

They were awarded the funds after all Phase 1 patients had already been treated. I guess that was my point.